We are live on
!
Find out more
LGM
Logos Global Management Portfolio holdings
AUM
$2B
1-Year Est. Return
444.09%
This Fund
S&P 500
This Quarter
Est. Return
-7.44%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$699M
AUM Growth
-$155M
(-18%)
Cap. Flow
-$60.3M
Cap. Flow
% of AUM
-8.64%
Top 10 Holdings %
Top 10 Hldgs %
51.76%
Holding
52
New
12
Increased
5
Reduced
17
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$27.7M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$20.8M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$17.2M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$15.6M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$14.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
APLS
Apellis Pharmaceuticals
APLS
|
+$31.7M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
+$20.7M |
| 3 |
BCYC
Bicycle Therapeutics
BCYC
|
+$17.2M |
| 4 |
VTYX
Ventyx Biosciences
VTYX
|
+$15M |
| 5 |
Fulcrum Therapeutics
FULC
|
+$14.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Disc Medicine
IRON
$2.85B
| $11.1M | 1.59% |
+525,000
| New | +$11.7M |
|
27
Cogent Biosciences
COGT
$6.91B
| $10.8M | 1.54% |
1,000,000
-100,000
| -9% | -$1.28M |
|
28
Biohaven
BHVN
$2.18B
| $9.56M | 1.37% |
+700,000
| New | +$11.1M |
|
|
VTYX
29
DELISTED
Ventyx Biosciences
VTYX
| $9.04M | 1.29% |
270,000
-387,016
| -59% | -$15M |
|
30
Enliven Therapeutics
ELVN
$3.77B
| $8.79M | 1.26% |
+401,229
| New | +$8.16M |
|
31
Structure Therapeutics
GPCR
$3.46B
| $8.33M | 1.19% |
+350,000
| New | +$8.22M |
|
32
Geron
GERN
$949M
| $7.7M | 1.1% |
3,550,000
-450,000
| -11% | -$1.28M |
|
33
ALX Oncology
ALXO
$272M
| $6.78M | 0.97% |
1,500,000
-849,600
| -36% | -$6.44M |
|
|
MOR
34
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $5.94M | 0.85% |
1,500,000
+600,000
| +67% | +$2.64M |
|
|
KYNB
35
Kyntra Bio
KYNB
$28.5M
| $5.6M | 0.8% |
12,000
-9,000
| -43% | -$4.76M |
|
36
Mineralys Therapeutics
MLYS
$2.4B
| $4.7M | 0.67% |
+300,000
| New | +$5.05M |
|
|
CBAY
37
DELISTED
Cymabay Therapeutics
CBAY
| $3.49M | 0.5% |
400,000
-850,000
| -68% | -$6.8M |
|
|
VIGL
38
DELISTED
Vigil Neuroscience
VIGL
| $1.84M | 0.26% |
188,390
| – | – |
|
39
Tyra Biosciences
TYRA
$1.85B
| $1.41M | 0.2% |
87,673
-23,183
| -21% | -$276K |
|
40
Aligos Therapeutics
ALGS
$25.2M
| $874K | 0.13% |
+40,000
| New | +$1.53M |
|
41
Immunic
IMUX
$188M
| $628K | 0.09% |
+42,118
| New | +$782K |
|
|
LIAN
42
DELISTED
LianBio American Depositary Shares
LIAN
| $549K | 0.08% |
280,000
| – | – |
|
|
NUVB.WS
43
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
| $8K | ﹤0.01% |
66,666
| – | – |
|
44
AnaptysBio
ANAB
$1.59B
| – | – |
-250,000
| Closed | -$7.75M |
|
|
45
Arcutis Biotherapeutics
ARQT
$3.48B
| – | – |
-1,400,000
| Closed | -$20.7M |
|
|
46
Fulcrum Therapeutics
FULC
$249M
| – | – |
-2,000,000
| Closed | -$14.6M |
|
|
RAPT
47
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-25,000
| Closed | -$3.96M |
|
48
Vera Therapeutics
VERA
$2.53B
| – | – |
-285,000
| Closed | -$5.51M |
|
|
SPRB
49
Spruce Biosciences
SPRB
$116M
| – | – |
-13,333
| Closed | -$1.1M |
|
|
CERE
50
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| – | – |
-260,000
| Closed | -$8.2M |
|
Similar funds
MYAM
RCM
LBC
C
CAM
BGM
SC
AF
Logos Global Management's Q1 2023 Portfolio in Review
As of Q1 2023, Logos Global Management held 52 positions worth $699M, down 18% from $854M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Logos Global Management withdrew a net $60.3M in Q1 2023, closing 9 positions and reducing 17 holdings. Its most notable exit was Arcutis Biotherapeutics, an estimated $20.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.
Against the trend, Logos Global Management opened a new position in Biogen worth $27.8M.
- Logos Global Management's largest Q1 2023 buy was Biogen: 100,000 shares worth $27.8M.
- Logos Global Management added most to Rocket Pharmaceuticals in Q1 2023, an estimated $2.94M increase.
- Logos Global Management's biggest Q1 2023 reduction was Apellis Pharmaceuticals, cutting an estimated $31.7M.
- Logos Global Management fully exited Arcutis Biotherapeutics in Q1 2023, selling an estimated $20.7M.
- Logos Global Management's ten largest holdings make up 52% of its $699M portfolio in Q1 2023.
- Logos Global Management opened 12 new positions and closed 9 in Q1 2023.
- Logos Global Management's portfolio value fell 18% quarter-over-quarter to $699M.
Based on Logos Global Management's 13F filing for Q1 2023, filed 15 May 2023.